Company: RPTX
Filing Date: 2025-02-25
Form Type: 8-K
Source: 0001193125-25-033718
Chunk: 0

Company: Repare Therapeutics Inc.
Filing Date: 2025-02-25
Form: 8-K
Item: Item 2.05
Chunk 0
---
Item 2.05  Costs Associated with Exit or Disposal Activities.

In January 2025, Repare Therapeutics Inc. (the “ Company”) announced a re-alignmentof resources and a re-prioritizationof its clinical portfolio to focus on the continued advancement of its Phase 1 clinical programs, RP-1664(PLK4 inhibitor) andRP-3467(Pol qATPase inhibitor). On February 23, 2025, the Board of Directors of the Company formally approved a plan to reduce the Company’s overall workforce by approximately 75% (the “ Reorganization”). These plans were communicated to affected employees on February 24, 2025.

The Company expects to incur one-timecash charges associated with the Reorganization of approximately $7.3 million related to employee severance payments and related costs, which are expected to be incurred through the fourth quarter of 2025. In addition, the Company has committed to pay one-timeemployee retention costs of up to approximately $1.4 million, which are expected to be incurred through the fourth quarter of 2025. The Company expects the Reorganization will be substantially complete by the fourth quarter of 2025. The Company expects the Reorganization will result in annual operating expense savings of approximately $21.0 million.

The estimates of the charges and expenditures that the Company expects to incur in connection with the Reorganization, and the timing thereof, are subject to several assumptions and the actual amounts incurred may differ materially from these estimates. In addition, the Company may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the Reorganization.